ReviewDrugs2019
Tofacitinib: A Review in Psoriatic Arthritis.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- The nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasis.Frontiers in immunology · 2025Article
- The Saudi consensus recommendations for the management of psoriatic arthritis (2023).Clinical rheumatology · 2024Review
- Single-cell sequencing analysis and multiple machine-learning models revealed the cellular crosstalk of dendritic cells and identified FABP5 and KLRB1 as novel biomarkers for psoriasis.Frontiers in immunology · 2024Article
- Article
- Fatigue in Inflammatory Joint Diseases.International journal of molecular sciences · 2023Review
- Various Application of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective.Dermatology practical & conceptual · 2022Review
- Therapeutic potential of pyrrole and pyrrolidine analogs: an update.Molecular diversity · 2022Review
- EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation.Nature cell biology · 2022Article
- IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.Clinical reviews in allergy & immunology · 2021Review
- Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates.Molecules (Basel, Switzerland) · 2020Review
- Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin.Mediterranean journal of rheumatology · 2020Article
- Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.Journal of experimental pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tofacitinib (Xeljanz
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.